Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBV-specific T-cell immunotherapy after chemotherapy for metastatic nasopharyngeal carcinoma
ACTRN12613000866707Phase 2Terminated
- Sponsor
- QIMR Berghofer Medical Research Institute
- Start
- Sep 2015
- Modality
- Small Molecules, Cell Therapies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of autologous LMP/EBNA1-specific EBV-specific T cells, gemcitabine and cisplatin in nasopharyngeal carcinoma (NPC), sponsored by QIMR Berghofer Medical Research Institute. Primary endpoints: Progression-free survival and Safety and tolerability. Started Sep 2015; status: terminated.
02
Drugs
autologous LMP/EBNA1-specific EBV-specific T cellsgemcitabinecisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ACTRN12613000866707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000866707.